ClinicalTrials.gg
CompletedNCT02057718INDIGOUpdated Oct 23, 2023Results posted

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

A Phase 2 interventional study of LUM001 (Maralixibat) in Progressive Familial Intrahepatic Cholestasis (PFIC), sponsored by Mirum Pharmaceuticals, Inc.. Completed at 10 sites in 4 countries. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
12 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Cholestasis, progressive familial intrahepatic 1 · United States.

Started
2014
with 1 other
Phase 2
2 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
6 of 10
Mirum Pharmaceuticals, Inc.

Among the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, this one is one of 2 that started in 2014, is one of 2 in phase 2, and was the 3rd registered.

Cholestasis, progressive familial intrahepatic 1

33 studies on the registry are indexed under Cholestasis, progressive familial intrahepatic 1; 13 are open to participants now.

Browse Cholestasis, progressive familial intrahepatic 1 studies →

Open to participants now

1 of the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Cholestasis, progressive familial intrahepatic 1 studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 12 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, or all of them as a file.
02

Study summary

This is an open label study in children with Progressive Familial Intrahepatic Cholestasis (PFIC) designed to evaluate the safety and efficacy of LUM001, also known as Maralixibat (MRX). Efficacy will be assessed by evaluating the effect of LUM001 on pruritus and the biochemical markers of pruritus associated with PFIC.

Read the detailed description

The study is divided into 5 parts: a 4-week dose escalation period, a 4-week stable dosing period, a 5-week stable dosing period, a 59-week long-term exposure period, and an optional follow-up treatment period for eligible participants who continue treatment with LUM001. Participants in the optional follow-up treatment period will continue to receive study drug until they are eligible to enter another LUM001 study or until LUM001 is available commercially, whichever occurs first.

03

Conditions studied

  • Progressive Familial Intrahepatic Cholestasis (PFIC)

Keywords

  • Bile duct diseases
  • Intrahepatic Cholestasis
  • Cholestasis
  • PFIC
  • Pruritus
  • Cholestatic Liver Disease
04

Who can participate

Ages eligible
12 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between the ages of 12 months and 18 years inclusive.
  1. Diagnosis of PFIC based on:
  1. Intrahepatic cholestasis manifest by total serum bile acid >3x (ULN) for age and, b or c:
  2. Two documented mutant alleles in ATP8B1, or ABCB11.
  3. Evidence of chronic liver disease, excluding those listed in (see Section 16.3), with one or more of the following criteria:

    1. Duration of biochemical or clinical abnormalities of >6 months, or
    2. Pathologic evidence of progressive liver disease, or
    3. Sibling of known individual affected by PFIC (predicted to be chronic).
    1. GGTP \<100 IU/L at screening. 4. Females of must have a negative urine or serum pregnancy test [β human chorionic gonadotropin (β-hCG)] during screening and a negative urine pregnancy test at the Baseline (Day 0) visit.
    1. Males and females of child-bearing potential who are sexually active, or are not currently sexually active during the study, but become sexually active during the period of the study and 30 days following the last dose of study drug, must agree and use acceptable during the trial, as described in Section 8.7.1. of the protocol 6. and assent (per IRB/EC) as appropriate. 7. Access to phone for scheduled calls from study site. 8. Caregivers and children above the age of assent must have the ability to read and understand one of the following languages: English, Spanish, US Spanish, French, German or Polish.
    1. Subjects expected to have a consistent caregiver(s) for the duration of the first 13 weeks of the study.
    1. Caregivers (and age appropriate subjects) must be willing and able to use an eDiary device as required by the study. To accommodate potential cultural restrictions within the FIC1 affected population a paper version of the ItchRO diary will be made available.
    1. Caregivers (and age appropriate subjects) using the eDiary must digitally accept the licensing agreement in the eDiary software at the outset of the study.
    1. Caregivers (and age appropriate subjects) must complete at least 10 eDiary reports (morning or evening) during each of two consecutive weeks of the screening period, prior to assignment (maximum possible reports = 14 per week). Subjects using a paper diary must complete the same number of reports within the same timeframe

Exclusion criteria

Exclusion Criteria

  1. Chronic diarrhea requiring specific intravenous fluid or nutritional intervention for the diarrhea and/or its sequelae.
  2. Surgical disruption of the enterohepatic circulation at the time at screening. Subjects who have undergone reversal of a prior surgical procedure intended to disrupt enterohepatic circulation and who and have a permanently restored flow of bile acids from the liver to the terminal ileum may be eligible for the study upon consultation with the Medical Monitor.
  3. Liver transplant.
  4. Decompensated cirrhosis [ (INR) > 1.5, albumin \< 30 g/L, history or presence of ascites, variceal hemorrhage, and/or encephalopathy].
  5. >15× at screening.
  6. History or presence of other liver disease (see Section 16.3).
  7. History or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs, including bile salt metabolism in the intestine (e.g., inflammatory bowel disease).
  8. Liver mass on imaging.
  9. Known diagnosis of (HIV) infection.
  10. Cancers except for in situ carcinoma, or cancers treated at least 5 years prior to screening with no evidence of recurrence.
  11. Any female who is pregnant or lactating or who is planning to become pregnant within 20 weeks of assignment.
  12. Any known history of alcohol or substance abuse.
  13. Administration of bile acid or lipid binding resins within 30 days prior to Baseline / Day 0 and throughout the trial.
  14. Administration of sodium phenylbutyrate within 30 days prior to Baseline / Day 0 and throughout the trial.
  15. drug, biologic, or medical device within 30 days prior to screening, or 5 half-lives of the study agent, whichever is longer.
  16. History of non-adherence to medical regimens, unreliability, mental instability or incompetence that could compromise the validity of or lead to non-adherence with the study protocol based on Investigator judgment.
  17. Any other conditions or abnormalities which, in the opinion of the Investigator or Medical monitor, may compromise the safety of the subject, or interfere with the subject participating in or completing the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    LUM001 (Maralixibat)

    Participants will receive LUM001, also known as Maralixibat (MRX) twice a day (BID).

    Drug: LUM001 (Maralixibat)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Endpoint (Week 13) in Fasting sBA Level

    Time frame: Baseline (Day 0) to Week 13

Secondary outcomes

  1. Change From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Obs)

    This secondary efficacy endpoint is the change from baseline to Week 13 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

    Time frame: Baseline (Day 0) to Week 13

  2. Change From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Pt)

    This secondary efficacy endpoint is the change from baseline to Week 13 in pruritus as measured by ItchRO(Pt) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

    Time frame: Baseline (Day 0) to Week 13

  3. Change From Baseline to Week 13/ET in ALT

    Time frame: Baseline (Day 0) to Week 13

  4. Change From Baseline to Week 13/ET in Total Bilirubin

    Time frame: Baseline (Day 0) to Week 13

  5. Change From Baseline to Week 13/ET in Direct Bilirubin

    Time frame: Baseline (Day 0) to Week 13

07

Results

Posted Jul 12, 2021
Limitations and caveats
Limitations of the trial such as small numbers of subjects analyzed or technical problems leading to unreliable data.

Participant flow

A total of 33 participants were enrolled at 11 sites in 4 countries (US, UK, France, Poland). Participants included 19 females and 14 males ranging from 1 to 13 years of age. Screening, treatment and safety follow-up, was approximately 76 weeks after which participants had the option of continuing in the additional follow-up treatment period up to 287 weeks.

Completed Study Treatment Through Wk. 72
Participant flow — Completed Study Treatment Through Wk. 72
MilestoneProgressive Familial Intrahepatic Cholestasis 1 (PFIC1)Progressive Familial Intrahepatic Cholestasis 2 (PFIC2) (Overall)
Started825
Completed study treatment through week 72616
Completed616
Not completed29
Withdrew: Progressive disease02
Withdrew: Physician decision10
Withdrew: Non-compliance with study drug01
Withdrew: Adverse event03
Withdrew: Consent withdrawn by caregiver11
Withdrew: Consent withdrawn by subject01
Withdrew: Liver transplant01
Optional Follow-up Treatment Period
Participant flow — Optional Follow-up Treatment Period
MilestoneProgressive Familial Intrahepatic Cholestasis 1 (PFIC1)Progressive Familial Intrahepatic Cholestasis 2 (PFIC2) (Overall)
Started616
Completed48
Not completed28
Withdrew: Did not consent to protocol amendment13
Withdrew: Progressive disease01
Withdrew: Adverse event12
Withdrew: Liver transplant02

Outcome measures

PrimaryChange From Baseline to Endpoint (Week 13) in Fasting sBA Level
Time frame:
Baseline (Day 0) to Week 13
Reported as:
Mean · umol/L
Change From Baseline to Endpoint (Week 13) in Fasting sBA Level
umol/LMaralixibatPFIC1PFIC2 (Overall)
Change From Baseline to Endpoint (Week 13) in Fasting sBA Level-23 (-463 to 279)18 (-117 to 149)-38 (-463 to 279)
Statistical analysis
  • PFIC1 vs PFIC2 (Overall) · Mean difference (net): -23.304 · 95% CI -82.35 to 35.742
SecondaryChange From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Obs)

This secondary efficacy endpoint is the change from baseline to Week 13 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

Time frame:
Baseline (Day 0) to Week 13
Reported as:
Mean · scores on a scale
Change From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Obs)
scores on a scaleMaralixibatPFIC1PFIC2 (Overall)
Change From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Obs)-0.7 ± 0.65-0.8 ± 0.83-0.7 ± 0.59
SecondaryChange From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Pt)

This secondary efficacy endpoint is the change from baseline to Week 13 in pruritus as measured by ItchRO(Pt) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

Time frame:
Baseline (Day 0) to Week 13
Reported as:
Mean · scores on a scale
Change From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Pt)
scores on a scaleMaralixibatPFIC1PFIC2 (Overall)
Change From Baseline to Week 13/ET in Pruritus as Measured by ItchRO(Pt)-0.6 ± 0.57-0.4 ± 0.65-0.7 ± 0.57
SecondaryChange From Baseline to Week 13/ET in ALT
Time frame:
Baseline (Day 0) to Week 13
Reported as:
Mean · U/L
Change From Baseline to Week 13/ET in ALT
U/LMaralixibatPFIC1PFIC2 (Overall)
Change From Baseline to Week 13/ET in ALT-9 ± 61.8-2 ± 29.1-11 ± 70.1
SecondaryChange From Baseline to Week 13/ET in Total Bilirubin
Time frame:
Baseline (Day 0) to Week 13
Reported as:
Mean · mg/dL
Change From Baseline to Week 13/ET in Total Bilirubin
mg/dLMaralixibatPFIC1PFIC2 (Overall)
Change From Baseline to Week 13/ET in Total Bilirubin-0.2 ± 1.65-0.8 ± 2.95-0.0 ± 0.9
SecondaryChange From Baseline to Week 13/ET in Direct Bilirubin
Time frame:
Baseline (Day 0) to Week 13
Reported as:
Mean · mg/dL
Change From Baseline to Week 13/ET in Direct Bilirubin
mg/dLMaralixibatPFIC1PFIC2 (Overall)
Change From Baseline to Week 13/ET in Direct Bilirubin-0.1 ± 1.12-0.3 ± 1.93-0.0 ± 0.72

Adverse events

Collected over Baseline to end of treatment (up to 287 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Population0/33 (0%)15/33 (45.5%)33/33 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventSafety Population
Abdominal painGastrointestinal disorders2/33
DiarrhoeaGastrointestinal disorders2/33
GastroenteritisInfections and infestations2/33
Radius fractureInjury, poisoning and procedural complications1/33
Ulna fractureInjury, poisoning and procedural complications1/33
Upper limb fractureInjury, poisoning and procedural complications1/33
Enteral nutritionSurgical and medical procedures1/33
Gastrointestinal tube insertionSurgical and medical procedures1/33
Blood bilirubin increasedInvestigations1/33
International normalised ratio increasedInvestigations1/33
Most frequent other events
Showing 10 of 211
Most frequent other events
EventSafety Population
PyrexiaGeneral disorders20/33
DiarrhoeaGastrointestinal disorders19/33
CoughRespiratory, thoracic and mediastinal disorders18/33
VomitingGastrointestinal disorders17/33
Abdominal painGastrointestinal disorders15/33
NasopharyngitisInfections and infestations15/33
Oropharyngeal painRespiratory, thoracic and mediastinal disorders13/33
Upper respiratory tract infectionInfections and infestations11/33
PruritusSkin and subcutaneous tissue disorders10/33
EpistaxisRespiratory, thoracic and mediastinal disorders9/33

Baseline characteristics

Age, Customized
Age, Customized(Subjects)PFIC1PFIC2 (Overall)Total
<2 years167
2 to 4 years51015
5 to 8 years246
9 to 12 years044
13 to 18 years011
Sex: Female, Male
Sex: Female, Male(Participants)PFIC1PFIC2 (Overall)Total
Female21719
Male6814
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PFIC1PFIC2 (Overall)Total
Hispanic or Latino011
Not Hispanic or Latino82129
Unknown or Not Reported033
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PFIC1PFIC2 (Overall)Total
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American000
White62026
More than one race011
Unknown or Not Reported033
Region of Enrollment
Region of Enrollment(participants)PFIC1PFIC2 (Overall)Total
United States51015
Poland011
United Kingdom31114
France033
08

Study locations

10 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Hopital Femme Mere Enfant De Lyon
    Bron, 69677, France
  • The Children's Memorial Health Institute
    Warsaw, 04-730, Poland
  • Birmingham Children's Hospital
    Birmingham, West Midlands B4 6NH, United Kingdom
  • Leeds Teaching Hospital NHS Trust
    Leeds, LS1 3EX, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
09

References and documents

Publications

  • Loomes KM, Squires RH, Kelly D, Rajwal S, Soufi N, Lachaux A, Jankowska I, Mack C, Setchell KDR, Karthikeyan P, Kennedy C, Dorenbaum A, Desai NK, Garner W, Jaecklin T, Vig P, Miethke A, Thompson RJ. Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 study. Hepatol Commun. 2022 Sep;6(9):2379-2390. doi: 10.1002/hep4.1980. Epub 2022 May 4. PubMed 35507739 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in May 2020, 74 months.

Results were first posted in Jul 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2014
First posted
Feb 7, 2014
StartActual
Mar 1, 2014
Primary completionActual
May 8, 2020
CompletionActual
May 8, 2020
Results first posted
Jul 12, 2021
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02057718
Responsible party
Sponsor
First posted
Feb 7, 2014
Start date
Mar 1, 2014
Primary completion
May 8, 2020
Completion
May 8, 2020
Results posted
Jul 12, 2021
Last update
Oct 23, 2023

Study contacts

Study Director
study director · Mirum

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion